Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -30.13% | -24.42% | 0.83% | 100.11% | -45.09% |
| Total Depreciation and Amortization | -4.81% | -0.08% | -0.32% | 0.74% | -7.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 53.79% | -13.31% | -136.36% | 54.75% | 71.12% |
| Change in Net Operating Assets | -83.28% | 190.70% | -508.68% | -19.06% | -71.98% |
| Cash from Operations | -23.57% | 81.26% | -45.16% | 30.65% | -18.16% |
| Capital Expenditure | -64.58% | -18.15% | -9.31% | 33.60% | -50.61% |
| Sale of Property, Plant, and Equipment | -80.00% | 400.00% | -99.20% | -52.83% | 1,458.82% |
| Cash Acquisitions | 20.88% | -48.37% | 56.81% | -153.57% | 50.88% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 46.85% | -846.27% | 90.40% | -2,784.62% | 102.22% |
| Cash from Investing | 11.79% | -134.81% | 58.27% | -400.40% | 85.71% |
| Total Debt Issued | 34.21% | 208.57% | -100.89% | 1,390.46% | -590.32% |
| Total Debt Repaid | 72.48% | 10.50% | 29.21% | -2,776.39% | -38.46% |
| Issuance of Common Stock | 425.00% | 0.00% | 0.00% | -77.78% | 500.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 99.86% | -6,309.09% | 99.28% | -- | 100.00% |
| Other Financing Activities | 100.00% | -- | 100.00% | -- | 100.00% |
| Cash from Financing | 89.33% | -79.46% | 25.21% | -467.32% | 74.97% |
| Foreign Exchange rate Adjustments | 131.58% | 47.22% | -227.27% | -283.33% | 111.76% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 219.48% | -138.66% | -130.32% | -108.63% | 711.22% |